Not an actual patient.
Relapsing MS is unpredictable and your health considerations may change over time. An agile treatment plan can help your healthcare team adapt to your needs. With PONVORY®, your healthcare professional can be ready to help manage certain unexpected events you may face along your MS journey, including relapses and lesions or needing to pause therapy for vaccines, infections, or family planning.
PONVORY®, A ONCE-DAILY PILL FOR ADULTS WITH RELAPSING MS
Superior at reducing relapses* and the number of new and enlarging lesions* vs a proven oral therapy in a study lasting ~2 years
No disability progression for ~90% of people over 2 years, as measured by time to 3-month CDP†
Studied over 10 years across multiple studies showing PONVORY® has a proven safety profile and is generally well-tolerated‡
With your healthcare professional’s guidance, PONVORY® can be paused, if needed, and then restarted§
PONVORY® locks away immune cells (lymphocytes) without destroying them.¶ This means lymphocytes may return to normal levels 1 to 2 weeks after pausing,# which may be important when planning for certain vaccines or addressing infections
For those thinking about planning for a family,ll PONVORY® leaves the body naturally in ~7 days after pausing**
Always talk to your healthcare professional before pausing PONVORY® for any reason
CDP = confirmed disability progression; MS = multiple sclerosis.
*In a phase 3 study vs Aubagio® lasting ~2 years, PONVORY® was shown to reduce the average number of relapses per year and the average number of new gadolinium-enhancing T1 and new or enlarging T2 lesions.
†There was no statistically significant difference between treatment groups.
‡Includes the phase 3 study, the phase 2, 6-month, placebo-controlled study, and the uncontrolled extension studies.
§If PONVORY® is paused for 4 or more days in a row, treatment must be restarted with a new 14-Day Starter Pack.
¶The exact way PONVORY® works in MS is unknown, but it is believed to work by reducing the number of lymphocytes in the blood.
#In the phase 3 study, lymphocyte counts returned to normal range within 2 weeks after stopping PONVORY®.
llPONVORY® should not be taken during pregnancy. Tell your healthcare professional right away if you become pregnant or plan on becoming pregnant.
**No elimination procedure required.
JANSSEN CAREPATH SAVINGS PROGRAM
IF YOU USE COMMERCIAL INSURANCE
Eligible patients pay $0 per fill with an $18,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their Janssen medication. Terms expire at the end of each calendar year and may change. There is no income requirement. See program requirements at Ponvory.JanssenCarePathSavings.com.
GET THE CONVERSATION STARTED
Tips for talking with your healthcare professional about PONVORY®, including a downloadable discussion guide.
READY TO BEGIN YOUR TREATMENT JOURNEY WITH PONVORY®?
See what's ahead.
YOUR STORY COULD HELP OTHERS
